Scleroderma News reported on a study that found that lenabasum, a potential treatment of diffuse cutaneous scleroderma, was shown to be safe and beneficial for patients during a Phase 2 clinical trial.

HSS rheumatologist Robert F. Spiera, MD, the trial's principal investigator, presented research findings at the European League Against Rheumatism (EULAR) 2018 Annual Meeting in Amsterdam.

According to the article, the trial found that patients experienced improvements in inflammation and fibrosis.

"Our results are very encouraging and reinforce the positive findings from the double-blinded placebo-controlled part of the study with regard to safety and tolerability. We look forward to continuing our investigations to assess the role of lenabasum as a new treatment option for patients with diffuse cutaneous systemic sclerosis," said Dr. Spiera.

Read the full article at sclerodermanews.com.